ASHLEY BEHYMER: Open Payments
NPI 1568689396 · BETTENDORF, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$373 in 19 payments from 9 companies in 2025. Trend: 2023 $452 · 2024 $426 · 2025 $373
Food & beverage: $373
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| Novo Nordisk Inc | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| ABBVIE INC. | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
| Alkermes, Inc. | 1 | $22 |
Products named: REXULTI, CAPLYTA, TRINTELLIX, VRAYLAR, Auvelity, INGREZZA, Wegovy, ARISTADA.
Industry payments across IA — which companies pay providers there.
